Sodium cumenesulphonate

Acute Toxicity: inhalation

Administrative data

Endpoint:

acute toxicity: inhalation

Type of information:

experimental study

Adequacy of study:

key study

Reliability:

2 (reliable with restrictions)

Rationale for reliability incl. deficiencies:

study well documented, meets generally accepted scientific principles, acceptable for assessment

Data source

Reference

Reference Type:

publication

Title:

Letter to Soap & Detergent Association (dated September 26, 1977) summarizing study data.

Author:

Witco Chemical Corporation, Paterson,

Year:

1977

Bibliographic source:

New Jersey, USA. Letter to Soap & Detergent Association (dated September 26, 1977) summarizing study data. SDAHT09.

Materials and methods

Test guideline

Qualifier:

according to guideline

Guideline:

other: CPSC CFR1500.40 of the Federal Hazardous Substances Act

GLP compliance:

not specified

Test type:

acute toxic class method

Limit test:

no

Test material

Test material information

Constituent 1

Reference substance name:

Sodium cumenesulphonate

EC Number:

248-983-7

EC Name:

Sodium cumenesulphonate

Cas Number:

28348-53-0

Molecular formula:

C9H12O3S.Na

IUPAC Name:

sodium cumenesulphonate

Test material form:

solid

Test animals

Species:

rat

Strain:

Wistar

Sex:

male/female

Details on test animals or test system and environmental conditions:

TEST ANIMALS
- Age at study initiation: 8-week old
- Housing: stainless steel cylinders with conical nose pieces.
- Acclimation period: approximately one week

ENVIRONMENTAL CONDITIONS
- Temperature (°C): 25 to 26
- Humidity (%): 40 to 70
- Photoperiod (hrs dark / hrs light): 12/12

Administration / exposure

Route of administration:

inhalation: aerosol

Type of inhalation exposure:

whole body

Vehicle:

air

Details on inhalation exposure:

The collected amount of the test substance in the air sample was measured gravimetrically. Sample volumes were measured by means of a dry gas meter (type G 1.6, Actaris Meterfabriek B.V., Dordrecht, The Netherlands).
- Duration of observation period following administration: 14 days
- Frequency of observations and weighing: Observations for viability were recorded once before exposure on the day of exposure (test day 1), three times during exposure, immediately and 1 h after exposure on test day 1 and twice daily during the observation period. Each animal was examined three times during exposure, immediately and 1 h after exposure on test day 1 and once daily during the observation period. Observations were detailed and carefully recorded using explicitly defined scales as appropriate. Only grossly abnormal signs were detectable during exposure as the animals were restrained in the exposure tubes. The body weight of each animal was recorded on test days 1 (before exposure), 2, 4, 8 and 15 (before necropsy).

- Necropsy of survivors performed: yes
- Other examinations performed: clinical signs, body weight,

Analytical verification of test atmosphere concentrations:

no

Duration of exposure:

ca. 4 h

Concentrations:

770 mg/L

No. of animals per sex per dose:

Number of Animals per Dose: 10 (5 males, 5 females)

Control animals:

yes

Details on study design:

The collected amount of the test substance in the air sample was measured gravimetrically. Sample volumes were measured by means of a dry gas meter (type G 1.6, Actaris Meterfabriek B.V., Dordrecht, The Netherlands).
- Duration of observation period following administration: 14 days
- Frequency of observations and weighing: Observations for viability were recorded once before exposure on the day of exposure (test day 1), three times during exposure, immediately and 1 h after exposure on test day 1 and twice daily during the observation period. Each animal was examined three times during exposure, immediately and 1 h after exposure on test day 1 and once daily during the observation period. Observations were detailed and carefully recorded using explicitly defined scales as appropriate. Only grossly abnormal signs were detectable during exposure as the animals were restrained in the exposure tubes. The body weight of each animal was recorded on test days 1 (before exposure), 2, 4, 8 and 15 (before necropsy).

- Necropsy of survivors performed: yes
- Other examinations performed: clinical signs, body weight,

Results and discussion

Effect levels

Effect levels 1

Sex:

male/female

Dose descriptor:

LC50

Effect level:

> 770 mg/L air

Based on:

test mat.

Exp. duration:

4 h

Remarks on result:

other: powdered test substance

Effect levels 2

Sex:

male/female

Dose descriptor:

LC50

Effect level:

> 770 000 mg/m³ air

Based on:

test mat.

Exp. duration:

4 h

Mortality:

No mortality occurred.

Clinical signs:

other: No clinical signs were noted during exposure. After exposure, ptosis and/or piloerection were noted in two males and one female on Day 1 only.

Body weight:

Overall body weight gain in males and females was within the range expected for rats of this strain and age used in this type of study.

Gross pathology:

none

Any other information on results incl. tables

To convert mg/l into mg/m³     

1m³=1000L

        

1 mg/m³=mg/l x 1000, 770mg/l x1000=770 000 mg/m³

Applicant's summary and conclusion

Interpretation of results:

other: not classified

Remarks:

practically nontoxic

Conclusions:

The inhalatory LC50, 4h value of sodium cumenesulphonate in Albino Wistar rats was established to exceed 770 mg/L.

Executive summary:

The inhalatory LC50, 4h value of sodium cumenesulphonate in Albino  Wistar rats was established to exceed 770 mg/L.